Table 1 Patient demographics
From: CFTR regulates B cell activation and lymphoid follicle development
|  | Cystic fibrosis (n = 27) | Controls (n = 10) | p value |
|---|---|---|---|
Age (yr) | 15.9 ± 0.98 | 15.3 ± 0.65 | 0.71 |
Sex (M/F) | 15/12 | 5/5 | 0.77 |
Race or ethnic group (no.) | |||
  Caucasian | 25 |  |  |
  Hispanic | 1 |  |  |
  Native American | 1 |  |  |
Body-mass index (kg/m2) | 18.1 ± 2.2 |  |  |
Prebronchodilator FEV1 (% of predicted value) | 33.0 ± 0.04 |  |  |
Pancreatic insufficiency (no.) | 27/27 | Â | Â |
Airway colonization with: | |||
 Pseudomonas aeruginosa | 19/25 |  |  |
 Methicillin-resistant Staphylococcus aureus | 8/25 |  |  |
 Methicillin-sensitive Staphylocccus aureus | 9/25 |  |  |
 Burkholderia cepacia complex | 6/25 |  |  |
 Stenotrophomonas maltophilia | 7/25 |  |  |
 Escherichia coli | 3/25 |  |  |
 Enterobacter species | 1/25 |  |  |
 Klebsiella species | 1/25 |  |  |
 Other Staphylococcus species | 1/25 |  |  |
CFTR genotype | |||
  Homozygous F508del-CFTR | 14 |  |  |
  Heterozygous F508del-CFTR | 4 |  |  |
  Heterozygous other | 1 |  |  |
  Unknown | 8 |  |  |
Pancreatic insufficiency (no.) | 27/27 | Â | Â |
CF-related diabetes mellitus (no.) | 13/27 | Â | Â |
CF-related liver disease (no.) | 5/27 | Â | Â |
Non-tuberculous mycobacteria lung infection (no.) | 1/21 | Â | Â |
Allergic bronchopulmonary aspergillosis (no.) | 4/27 | Â | Â |
Immunoglobulin E (mg/dL) | 278 ± 107.5 |  |  |